YCC has proven to be a global leader in cancer care, research and education with $89M in direct cancer funding, which includes $24M in NCI funding. The National Cancer Institute (NCI) may award a CCSG to any non-profit institution within the United States with a peer-reviewed cancer research base of at least 4 million dollars. The objective of a CCSG is not to directly support research projects, but to enhance, strengthen, and increase the institution’s ongoing cancer research with the ultimate goal of reducing cancer incidence, mortality, and morbidity. The CCSG provides the resources and infrastructure to facilitate the coordination of YCC’s seven interdisciplinary research programs from basic laboratory research to clinical investigations including therapeutic clinical trials to population sciences that look into the question of how to reduce the risk, incidence, and death from cancer, as well as enhance the quality of life for cancer survivors.
Through 43 years of continuous funding, YCC has demonstrated that it provides:
- Cancer research that spans laboratory science, clinical research, and population-based research.
- Clinical programs that offer patients the latest forms of treatment for a wide range of cancers, as well as access to clinical trials of experimental treatments.
- Training for scientists, physicians, surgeons, and other professionals seeking specialized training or board certification in cancer-related disciplines
- Public education and outreach about cancer prevention and screening, with special attention to the needs of underserved populations.
- Substantial transdisciplinary research that bridges these scientific areas.
- Demonstrated professional and public education and outreach capabilities, including dissemination of clinical and public health advances in the communities it serves.